| Prev Close: | 4.87 |
|---|---|
| Open: | 4.88 |
| Bid: | 4.86 x 2000 |
| Ask: | 4.87 x 500 |
| 1y Target Est: | 8.25 |
| Beta: | 2.18 |
| Next Earnings Date: | 24-Jun-13 |
| Day's Range: | 4.81 - 4.89 |
|---|---|
| 52wk Range: | 3.68 - 7.58 |
| Volume: | 17,427 |
| Avg Vol (3m): | 222,111 |
| Market Cap: | 260.10M |
| P/E (ttm): | 30.38 |
| EPS (ttm): | 0.16 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- See How SciClone Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activityat Forbes(Mon, Jun 10)
- SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, May 31)
- SciClone to Present at Jefferies 2013 Global Healthcare ConferenceMarketwired(Tue, May 28)
- China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failure Drugat Seeking Alpha(Sun, May 19)
- 4 Healthcare Stock Stories For Thursday Investing Wellnessat Wall St. Cheat Sheet(Thu, May 16)
- SciClone Reports Anticipated Financial Results for the First Quarter 2013Marketwired(Thu, May 16)
- SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China MarketMarketwired(Thu, May 16)
- Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert Portfolio Manager Finny Kuruvilla Discusses His Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations anEDGAR Online(Thu, May 16)
- Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Marginsat Seeking Alpha(Fri, May 10)
- Emerging Markets an Area of Opportunity for Global Generic Players: An Expert Analyst Gives His Take on the Generic Drug SpaceWall Street Transcript(Thu, May 2)
- SciClone appoints PricewaterhouseCoopers as independent accounting firmtheflyonthewall.com(Mon, Apr 8)
- SciClone Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting FirmMarketwired(Mon, Apr 8)
- SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial StatementsEDGAR Online(Sun, Apr 7)
- SCICLONE PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, Apr 5)
Press Releases
- SciClone to Present at Jefferies 2013 Global Healthcare ConferenceMarketwired(Tue, May 28)
- SciClone Reports Anticipated Financial Results for the First Quarter 2013Marketwired(Thu, May 16)
- SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China MarketMarketwired(Thu, May 16)
Reports
- SCLN: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 19)
- ValuEngine Industry Report for Medical-drugsValuEngine, Inc.(Jun 19)
- SCLN - SciClone Pharmaceuticals Inc - Rated a Hold - Company Analysis and ASR...Alpha Street Research(Jun 18)